BEBT-305

Clinical trials in healthy volunteers: Primary objectives: To evaluate the safety and tolerability of BEBT-305 in healthy volunteers; To evaluate the pharmacokinetic characteristics of BEBT-305 in healthy volunteers; To evaluate the effect of food on the pharmacokinetics of BEBT-305. Clinical trials in patients with moderate to severe plaque psoriasis: Primary objectives: To evaluate the safety and tolerability of BEBT-305 in patients with moderate to severe plaque psoriasis. Secondary objectives: To evaluate the pharmacokinetic characteristics of BEBT-305 in patients with moderate to severe plaque psoriasis; To explore the effective dose of BEBT-305 for the treatment of patients with moderate to severe plaque psoriasis, i.e. the recommended dose (RP2D) for Phase II clinical trials. Exploratory objectives: To explore the guiding significance of changes in skin and blood biomarkers on the safety and pharmacodynamics of BEBT-305 in the treatment of patients with moderate to severe plaque psoriasis.